<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01000649</url>
  </required_header>
  <id_info>
    <org_study_id>FE 202158 CS02</org_study_id>
    <secondary_id>EudraCT: 2009-010798-19</secondary_id>
    <nct_id>NCT01000649</nct_id>
  </id_info>
  <brief_title>Effects of the V1a Agonist FE 202158 in Patients With Septic Shock</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Infusion Proof-of-concept Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of FE 202158 in Patients With Vasodilatory Hypotension in Early Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to examine the safety and tolerability, pharmacokinetics of
      FE202158 and to assess whether it can stabilize blood pressure and reduce vascular (blood
      vessel) leakage. FE 202158 has previously been tested in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stabilisation of blood pressure - Proportion of patients maintaining target MAP with no open label NE (Norepinephrine)</measure>
    <time_frame>Day 1- 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients maintaining target MAP</measure>
    <time_frame>Day 1-7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative dose and infusion rates of open label NE.</measure>
    <time_frame>Day 1-7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of FE 202158 in patients (clearance, half life)</measure>
    <time_frame>Day 1 - day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Day 1 - day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Day 1 - day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular leakage</measure>
    <time_frame>Day 1 - day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response</measure>
    <time_frame>Day 1 - day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - changes in vital signs, clinical chemistry, haemostasis and urinalysis</measure>
    <time_frame>Day 1 - day 7, day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability - changes in vital signs, clinical chemistry, haemostasis and urinalysis</measure>
    <time_frame>Day 1 - day 7, day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>Day 1 - day 7, day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>Day 1 - day 7, day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Frequency and intensity of adverse events</measure>
    <time_frame>Day 1 - day 7, day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability - Frequency and intensity of adverse events</measure>
    <time_frame>Day 1 - day 7, day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 202158</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form by the patient or a legal representative according to
             local regulations

          -  Man or woman 18 years of age or older

          -  Proven or suspected infection

          -  Low blood pressure

          -  Signs of decreased circulation in the tissues

          -  Willing to use an adequate barrier method or hormonal method of contraception, if not
             abstinent, from the day of informed consent to one week after the end of infusion of
             study medication.

        Exclusion Criteria:

          -  Present or a history (within the last 5 years) of acute coronary syndrome (myocardial
             infarction or unstable angina). Patients who have been asymptomatic for 6 months
             after coronary revascularisation are eligible.

          -  Hypovolaemia suspected on clinical grounds, e.g. cold extremities with delayed
             capillary filling, low cardiac filling pressure, marked systolic or pulse pressure
             variation or positive leg raising test.

          -  Known or suspected cardiac failure

          -  Pregnancy or breastfeeding

          -  Any cause of hypotension other than early septic shock

          -  Use of vasopressin or terlipressin for blood pressure support during the current
             hospital admission

          -  Proven or suspected acute mesenteric ischemia, as judged by the investigator

          -  Known episode of septic shock within 1 month prior to randomisation

          -  Underlying chronic heart disease

          -  Traumatic brain injury

          -  Present hospitalisation with burn injury

          -  Symptomatic peripheral vascular disease including Raynaud's syndrome

          -  Previously randomised in this trial

          -  Intake of an investigational drug within the last 3 months (or longer if judged by
             the Investigator to possibly influence the outcome of the current study)

          -  Known participation in another clinical trial

          -  Considered by the investigator to be unsuitable to participate in the trial for any
             other reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baystate Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Education and Research SMDC Health System</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire St-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital (Free University of Brussels)</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Vrije Universiteit</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Soins Intensits</name>
      <address>
        <city>Dinant</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul´s Hospital</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Bispebjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hillerød Hospital</name>
      <address>
        <city>Hillerød</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 26, 2015</lastchanged_date>
  <firstreceived_date>September 30, 2009</firstreceived_date>
  <firstreceived_results_disposition_date>September 11, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>V1a agonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
